ZTS

ZTS

USD

Zoetis Inc. Class A Common Stock

$119.830-0.600 (-0.498%)

Preço em tempo real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$120.430

Máximo

$121.310

Mínimo

$118.520

Volume

8.35M

Fundamentos da empresa

Capitalização de mercado

52.8B

Setor

Drug Manufacturers - Specialty & Generic

País

United States

Estatísticas de negociação

Volume médio

3.12M

Bolsa de valores

NYQ

Moeda

USD

Faixa de 52 semanas

Mínimo $117.26Atual $119.830Máximo $181.85

Notícias relacionadas

Analyst Upgrades

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175

Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.

Ver mais
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Analyst Upgrades

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.

Ver mais
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
BusinessWire

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career

Ver mais
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
BusinessWire

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing

Ver mais
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
BusinessWire

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as

Ver mais
Zoetis Appoints Stephanie Tilenius to its Board of Directors